Clinical trials
New active compounds must be tested extensively to guarantee the efficacy, safety and security of new medications. This is done within the framework of clinical trials. Clinical trials are essential to improve medical care.
Patients who take part in such studies have the chance to be treated with innovative therapies earlier than others. Clinical trials are subject to clear legal regulations. All studies conducted in Germany must be approved by the Federal Institute for Drugs and Medical Devices (BfArM) or the Paul Ehrlich Institute (PEI). Both authorities are subordinate to the Federal Ministry of Health. In addition, these studies must be approved by the competent ethics committee.
Further information on clinical trials can be found on the website of the VfA (Association of Research-based Pharmaceutical Companies) and on our FAQ-website
Study: COVIMMUNE-Clin
Study title: Long-term effects of COVID-19 on pulmonary and neurocognitive disorders
DRKS-ID: DRKS00023806
Background:
Different reports suggest that an infection with SARS-CoV-2 can lead not only to damage to the lungs, but in rare cases also to permanent damage to the nervous system. Attention problems, memory or word finding disorders as well as lung damage and symptoms of fatigue are reported, among other things.
In order to research this further, we are investigating the possible effects and long-term consequences of an infection with SARS-CoV-2 on the nervous system, cognitive performance and the lungs as part of the “COVIMMUNE-Clin” study funded by the Federal Ministry of Education and Research.
Participation:
We are looking for participants between 25 and 75 years with an asymptomatic (SARS-CoV-2 positive) and severe disease course (hospital stay) as well as healthy participants as a control group, who will be examined at three measurement times at the beginning, after 6 and after 12 months.
Course of the study:
Cognitive performance (e.g. memory and attention), lung function, brain structure using an MRI and blood samples taken on the days of the examination are examined. The entire examinations will take approximately 5-6 hours to complete.
Start: March 2021
More information can be found here.
Contact Person:
If you have any questions, please contact the study team by email () stating your contact details. We will get back to you as soon as possible. Please support our research and help to gain a better understanding of the consequences of COVID-19.
Study: ANAVEX2-73-SF-004
Study title: A double-blind, randomized, placebo-controlled, 48-week Phase IIb/III study of the safety and efficacy of ANAVEX2-73 in the treatment of incipient Alzheimer's dementia
Substance: ANAVEX2-73
EudraCT NO: 2019-003302-27
Target group:
- Age between 60 and 85 years patients with mild Alzheimer's dementia or mild cognitive impairment
- Existing reference person/caregiver (more than 10 hours contact/week)
- No serious pre-/accompanying diseases (e.g. stroke)
Treatment duration: 52 weeks
Start: Recruitment completed
Further information:
https://clinicaltrials.gov/ct2/show/NCT03790709
Contact person:
Mrs. Carmen Sachtleben, Study Coordinator
Mrs. Sybille Fallert-Ouattara
Study: ROCK-ALS
Study title: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
Substance: Fasudil
EudraCT NO: 2017-003676-31
Target group:
- Patients with diagnosed amyotrophic lateral sclerosis and symptom onset >6 months and < 24 months
- >18 years
- Vital capacity >65%
Start: 2019 (since 12/2020 in Bonn)
Further information:
Study: GENERATION HD1
Study title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
Substance: Tominersen RO7234292 (RG6042)
EudraCT NO: 2018-003898-94
Objective: To evaluate efficacy, safety and biomarker effects of RO7234292 (RG6042) compared to placebo in patients (25-65 years) with manifest Huntington's disease.
Start: January 2019, recruitment completed
Further information:
